Literature DB >> 11595298

Monitoring HIV-specific CD8+ T cell responses by intracellular cytokine production.

M R Betts1, J P Casazza, R A Koup.   

Abstract

Human immunodeficiency virus (HIV)-specific CD8+ T cells play an important role in controlling HIV infection. Accurate monitoring of these cells is crucial in determining the effects of HIV therapy and vaccine efficacy. Using an intracellular cytokine staining based assay, we are able to directly quantify functional HIV-specific CD8+ T cells. This assay is highly reproducible, and can be performed using both fresh and cryopreserved peripheral blood cells. Importantly, this assay can be used to examine multiple HIV-peptide epitopes simultaneously, and is independent of patient HLA haplotype. Here, we examine the HIV-specific CD8+ T cell response to 95 optimized HIV-derived cytotoxic T lymphocyte (CTL) epitopes in 21 HIV-infected patients of varying HLA haplotype, using peptide mixes and matrices. We find that when using mixes of multiple HIV peptides, the CD8+ T cell response to the mixture is equivalent to the sum of the responses to the individual peptides contained therein. Detailed comparison of the responses in patients suggests that most patients generate a diverse CD8+ T cell response, recognizing multiple HIV epitopes derived from HIV Gag, Pol, Env, or Nef. Although some patients sharing HLA alleles occasionally recognize common peptides, rarely are responses to those peptides dominant within the same group of patients. These results confirm our previous findings that the responses to single HIV-peptides are rarely representative of the entire HIV response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595298     DOI: 10.1016/s0165-2478(01)00273-5

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  22 in total

1.  Functional discrepancies in HIV-specific CD8+ T-lymphocyte populations are related to plasma virus load.

Authors:  Annetie Oxenius; Andrew K Sewell; Sara J Dawson; Huldrych F Günthard; Marek Fischer; Geraldine M Gillespie; Sarah L Rowland-Jones; Catherine Fagard; Bernard Hirschel; Rodney E Phillips; David A Price
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

2.  Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.

Authors:  Emmanouil Papasavvas; Andrea Foulkes; Xiangfan Yin; Jocelin Joseph; Brian Ross; Livio Azzoni; Jay R Kostman; Karam Mounzer; Jane Shull; Luis J Montaner
Journal:  Immunology       Date:  2015-05-19       Impact factor: 7.397

3.  Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples.

Authors:  Wayne B Dyer; Sarah L Pett; John S Sullivan; Sean Emery; David A Cooper; Anthony D Kelleher; Andrew Lloyd; Sharon R Lewin
Journal:  Clin Vaccine Immunol       Date:  2006-10-18

4.  Role of avidity and breadth of the CD4 T cell response in progression to AIDS.

Authors:  Hester Korthals Altes; Rob de Boer; Maarten Boerlijst
Journal:  Proc Biol Sci       Date:  2006-07-07       Impact factor: 5.349

5.  Autologous CD4/CD8 co-culture assay: a physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-infected persons.

Authors:  Steven R Fauce; Otto O Yang; Rita B Effros
Journal:  J Immunol Methods       Date:  2007-08-08       Impact factor: 2.303

6.  Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.

Authors:  Lisa E Hensley; Sabue Mulangu; Clement Asiedu; Joshua Johnson; Anna N Honko; Daphne Stanley; Giulia Fabozzi; Stuart T Nichol; Thomas G Ksiazek; Pierre E Rollin; Victoria Wahl-Jensen; Michael Bailey; Peter B Jahrling; Mario Roederer; Richard A Koup; Nancy J Sullivan
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

7.  HIV-specific T-cell responses detected in the genital tract of chronically HIV-infected women are largely monofunctional.

Authors:  Alfred Bere; Lynette Denny; Prinola Naicker; Wendy A Burgers; Jo-Ann S Passmore
Journal:  Immunology       Date:  2013-07       Impact factor: 7.397

8.  Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.

Authors:  Mark J Boaz; Peter Hayes; Tony Tarragona; Laura Seamons; Andrew Cooper; Josephine Birungi; Paul Kitandwe; Aloysius Semaganda; Pontiano Kaleebu; Gwynneth Stevens; Omu Anzala; Bashir Farah; Simon Ogola; Jackton Indangasi; Patrick Mhlanga; Melanie Van Eeden; Madhuri Thakar; Ashwini Pujari; Shadri Mishra; Nilu Goonetilleke; Stephen Moore; Abdul Mahmoud; Pattabiraman Sathyamoorthy; Jayashri Mahalingam; Paranji R Narayanan; Vadakkuppattu D Ramanathan; Josephine H Cox; Len Dally; Dilbinder K Gill; Jill Gilmour
Journal:  Clin Vaccine Immunol       Date:  2008-12-17

9.  Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection.

Authors:  J Judy Chang; Sunee Sirivichayakul; Anchalee Avihingsanon; Alex J V Thompson; Peter Revill; David Iser; John Slavin; Supranee Buranapraditkun; Pip Marks; Gail Matthews; David A Cooper; Stephen J Kent; Paul U Cameron; Joe Sasadeusz; Paul Desmond; Stephen Locarnini; Gregory J Dore; Kiat Ruxrungtham; Sharon R Lewin
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

10.  Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells.

Authors:  Marybeth Daucher; David A Price; Jason M Brenchley; Laurie Lamoreaux; Julia A Metcalf; Catherine Rehm; Elizabeth Nies-Kraske; Elizabeth Urban; Christian Yoder; Diane Rock; Julie Gumkowski; Michael R Betts; Mark R Dybul; Daniel C Douek
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.